Biotinylation of erythrocytes (E) followed by avidin cross-linking at specific sites has been suggested as a novel means of drug delivery. Upon avidin cross-linking, biotinylated E become complement-activating and highly susceptible to complement lysis, thus bringing about release of entrapped drug. We set out to examine the mechanisms of this biotin-avidin-induced lytic susceptibility, focusing on the effects of biotinylation and avidin cross-linking on the major E complement regulatory molecules, decay accelerating factor (DAF) and CD59. We demonstrate here that biotinylation of E, which does not render them complement activating, partially inhibits DAF but has little effect on CD59. Subsequent cross-linking with avidin causes
INTRODUCTION
During the last few years the avidin-biotin complex has found wide application in different fields of biology and medicine [1] . The utility of avidin and biotin is based on the high affinity, high specificity and multivalency ofthe avidin-biotin interaction. Cells and other particles can be modified using biotin derivatives of different molecules, followed by avidin binding.
Our aim has been to utilize avidin-biotin interactions to deliver erythrocytes (E), carrying therapeutic agents, to specific sites in vivo [2] . A surprising finding from these early studies was that while biotinylated erythrocytes (BE) were not complement activating, subsequent binding of avidin to BE makes the cells efficient activators of the alternative pathway and additionally renders the cells highly susceptible to complement lysis [2, 3] . These effects were shown to be independent of the charge on the avidin and of the sugar moiety, but were dependent on the mode and site of avidin-biotin binding to the membrane [3] . Avidin cross-linking on E biotinylated on NH2-groups rendered cells complement sensitive, whereas attachment of avidin through a phospholipid derivative of biotin or through the cross-linking reagent tannin in the E membrane did not increase complement susceptibility f4,5]. The degree of complement susceptibility was also dependent on the length of the biotin residue attached through NH2-groups on the E; the N-caprolamine-succinimide ester of biotin caused more efficient lysis than the N-hydroxysuccinimide ester, a consequence of the aminocaproate group which provides an additional 6 A spacer arm, placing the biotin moiety further from the membrane [3] . Multivalency of avidin attachment to biotin on the E membrane also caused increased complement susceptibility [3] . Recently, we have begun to complete inhibition of DAF and near complete loss of CD59 activity. Followingcross-linking, DAF and CD59 become associated in high molecular mass avidin-containing complexes on the membrane. Incorporation of physiological amounts of CD59 into the membranes of biotinylated and avidin cross-linked E is sufficient to render these cells resistant to complement lysis whereas incorporation of DAF has relatively little effect. An understanding of the molecular mechanisms underlying complement susceptibility of biotin-avidin treated E should allow a rational design of strategies for drug delivery using E or other large, potentially complement-activating carriers.
examine whether this phenomenon can be utilized to cause release of entrapped agent at targeted sites 16 ].
The precise mechanism by which avidin cross-linking of biotin on the E membrane causes activation of the alternative pathway and increased lytic susceptibility have yet to be ascertained. One possible explanation of the enhanced lytic susceptibility is that the cross-linking event inactivates membrane complement regulatory proteins [3, 6] . Complement activation is controlled on the surface of E and other cells by several membrane proteins acting at two distinct stages in the activation cascade [7, 8] . The complement 3 (C3) and C5 cleaving enzymes of the activation pathways are regulated by three molecules, decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and complement receptor 1 (CR1, CD35). The membrane attack pathway is regulated by two molecules, CD59 and homologous restriction factor (HRF). E do not express MCP and express CR1 in very low amounts (100-1000 copies per cell; [9, 10] ), probably insufficient to influence lysis [11, 121 . HRF is poorly characterized and is probably of little relevance to E protection [13] . The major complement protective proteins on human E are therefore DAF (E expression 3.3 x 103 copies per cell; [14] ) and CD59 {(1-4) x 104 copies per E; [15, 16] }. This contention is supported by the observation that E from patients with paroxysmal nocturnal haemoglobinuria (PNH), which are deficient in the glycosylphosphatidylinositol (GPI)-linked inhibitors DAF and CD59 but express CR1 in normal amounts, exhibit greatly enhanced lytic susceptibility [17] .
The purpose of the present investigation was therefore to examine whether the enhanced complement susceptibility of E following biotin-avidin treatment was caused by the effects of Blood, sera, antibodies and other proteins
Blood from healthy volunteers of blood group A or AB was collected in Alsever's solution (114 mM citrate/27 mM glucose/72 mM NaCl, pH 6.1) and stored at 4 'C. Normal human serum (NHS) was obtained from volunteers and stored in aliquots at -70 'C until use. Human serum depleted of C8 (HS-C8) and C9 (HS-C9) were produced by passage of human serum over immunoaffinity columns of anti-(human)-C8 or anti-(human)-C9 antibodies respectively as previously described [18, 19] . Human CD59 was purified from E membranes by affinity chromatography as previously described [20] . DAF was affinity purified from the same membranes using the monoclonal antibody (mAb) BRICi 10 Biotinylation and avidin treatment of E Biotinylation of E with (6-biotinylamido)-N-hydroxysuccinimide ester to form BE and subsequent avidin binding to form avidincoated BE (AvBE) were performed as described previously [2] . In brief, 0.1 ml of 0.1 M sodium tetraborate (pH 9.0) and 3,l of the biotin ester (0.1 M in dimethylformamide) were mixed with 1 ml of a 10 % suspension of E in PBS. After 20 min of incubation at room temperature, BE were washed four times with PBS. Avidin (5 #1 of 1 mg/ml in PBS) was added to 100,l ofa 10 % suspension of BE and incubated for 20 min at 4 'C. AvBE were washed three times in PBS and resuspended in VBS.
Haemolytic assay
Haemolytic assays were carried out in 96-well microtitre plates. ( Figure la) . The antibodies BRIC229 and BRIC216/BRICl 10, which are not themselves complement-fixing, neutralize CD59 and DAF respectively, and thereby render antibody-sensitized E and BE more susceptible to complement lysis (Figures lb and  lc) . Indeed, the combination of these antibodies rendered sensitized E almost as susceptible to lysis as AvBE (Figure lb) . The effect of blocking DAF on BE was small, suggesting that biotinylation effectively inhibited DAF (Figure ic) . In contrast to E and BE, AvBE were highly susceptible to complement lysis even in the absence of sensitizing antibody (Figure la) . Anti-DAF antibodies caused no further enhancement of lytic susceptibility of AvBE, implying that this inhibitor had been completely neutralized by treatment with avidin-biotin ( Figure  Id) . However, anti-CD59 antibody did induce some increased complement susceptibility on AvBE, indicating that residual active CD59 was present on the cell (Figure ld ).
-. [241. The therapeutic strategy would be, first to infuse a tissue-(or tumour-) specific antibody conjugated with biotin, follow this with avidin to localize avidin in the correct site and finally add BE which will localize in the same region as the antibody [6] .
Release of therapeutic agent requires that the AvBE is lysed at that site. When biotin is attached through amino groups and at sufficient density to E membrane proteins, this will occur through the induction of complement-activating capacity and lytic susceptibility upon cross-linking with avidin [4] [5] [6] 24] . In the present study we set out to investigate the roles of E membrane complement regulatory molecules in this avidin-induced complement lytic susceptibility. The major membrane complement regulators on E are DAF, inhibiting at the C3/C5 convertase stage and CD59, which inhibits assembly of the lytic MAC [8] . Both of these proteins are abundantly expressed and anchored by GPI on the E surface and their importance in the regulation of E lysis is dramatically illustrated in the disease PNH, where both these proteins are deficient on the abnormal clone [17] . We therefore focused our studies on the effects of biotinylation and subsequent avidin cross-linking of these two molecules.
Although BE are not spontaneously lysed by complement, their susceptibility to lysis in the presence of a complementactivating antibody had not previously been examined. We found that BE were substanti-ally more susceptible to antibodymediated complement lysis than were untreated E, implying that biotinylation alone had a significant inhibitory effect on complement regulation on the E surface. The antibodies BRIC229 (IgG2b, anti-CD59) and the combination of BRICI 10 and BRIC216 (both IgGl, anti-DAF) neutralize the complementinhibiting activities of their respective ligands and render target cells more susceptible to complement lysis. None of these antibodies has any intrinsic complement activating capacity [25] [26] [27] biotinylation. In contrast, neutralization of DAF caused little further increase in lytic susceptibility, suggesting that DAF was strongly inhibited by biotinylation alone (Figures la and lc) . DAF operates predominantly in the classical pathway [8] , which explains the finding that biotinylation had its most marked effect on lysis of antibody-sensitized E (classical pathway; Figure la) . AvBE spontaneously activated complement and were easily lysed even in the absence of activating antibody. Addition of anti-DAF antibody to AvBE caused no further enhancement of lytic susceptibility, implying that this inhibitor was completely blocked by avidin-biotin treatment, whereas addition of anti-CD59 did further increase lysis, indicating that CD59 was incompletely blocked by avidin-biotin (Figures la and d) . E express about 3 x 103 molecules of DAF and between 1 x 104 and 4 x 104 molecules of CD59 [14] [15] [16] . Given this almost 10-fold excess of CD59 and its smaller molecular size (approx. 20 kDa as opposed to 60 kDa for DAF) it is perhaps not surprising that neutralization by avidin-biotin was less complete. FACScan analysis revealed that biotinylation alone caused a decrease in antibody staining of about 20 % for CD59 (BRIC229) and nearly 30 % for DAF (BRIC216); subsequent cross-linking with avidin further reduced binding of anti-CD59 (60 %) whereas binding of anti-CD55 was little changed (32 %) (Figure 2) . Hence, complete inhibition of DAF activity was achieved with only a 32 % loss of the BRIC216 epitope whereas CD59 was incompletely inhibited despite a 60 % loss of the BRIC229 epitope. These findings again reflect the difference in size between these two proteins.
In order to confirm that CD59 was significantly inhibited on AvBE we made C5b-7 sites on BE before cross-linking with avidin. BE bearing C5b-7 sites were not lysed upon subsequent addition of C8 and C9 whereas BEC5b-7 cross-linked with avidin were efficiently lysed by C8 and C9. We have previously demonstrated that AvBE are not more susceptible to 'nonspecific' lysis mediated through osmotic shock, melittin or perforin [6] . These results thus demonstrate that avidin crosslinking does neutralize a substantial proportion of the CD59 and render E susceptible to MAC lysis (Figure 3) . BE which were cross-linked with avidin before the formation of C5b-7 sites were extremely susceptible to MAC lysis, presumably as a consequence of increased complement activation and DAF neutralization, allowing the formation of more C5b-7 sites on the cell.
The fate of CD59 and DAF on the membranes of BE and AvBE was further explored by immunoblotting. Biotinylation (molecular mass of biotin moiety approx. 340 Da) caused no discernible alteration in the molecular mass of either DAF or CD59 (Figures 5a and 5b; lane 1) , suggesting that only a few copies of biotin were bound per protein molecule. However, the signal obtained on blotting was diminished, suggesting that there was some hindrance of antibody binding to biotinylated protein, as was noted for FACS analysis. Avidin cross-linking caused a dramatic change in the pattern for DAF and CD59; all the DAF migrated as a high molecular mass complex (> 200000 Da), as did the bulk of the CD59 (Figures 5a and 5b ; lane 3), indicating that these two proteins were entrapped in the same or similar complexes on the E surface. Probing of blots of BE membranes with streptavidin peroxidase revealed the full range of biotinylated proteins and highlighted bands of identical sizes with those detected by anti-CD59 and anti-DAF (indicated with an arrow in Figures 5c and 5d) , demonstrating that these proteins were efficiently biotinylated at the E surface.
Although the above findings implicate neutralization of DAF and CD59 in the enhanced complement lytic susceptibility of AvBE they do not rule out the-possibility that other surface changes contribute. In order to assess this possibility, purified CD59 and DAF were incorporated into BE at doses sufficient to double the surface expression of these inhibitors. Incorporation of either DAF or CD59 caused diminished complement lytic susceptibility when the cells were subsequently cross-linked with avidin, CD59 being the more efficient inhibitor (Figure 4) . However, even combined incorporation of the two inhibitors at a dose sufficient to double inhibitor levels on the cells ([27] and C. W. Van den Berg and B. P. Morgan, unpublished work) did not decrease lytic susceptibility to the level of untreated BE, suggesting that additional factors were also involved. It is possible that HRF is one of these factors but HRF plays a minor role in the protection of E [13] , hence other factors may also contribute.
In the present study we do not directly address the mechanism by which avidin cross-linking causes BE to become activators of the alternative pathway. One possibility is that neutralization of DAF, described above, is itself sufficient to render the surface activating. However, this is unlikely as biotinylation alone apppears to effectively inhibit DAF, and neither this nor neutralization of DAF with mAb causes E to activate complement spontaneously. A direct complement-activating effect of the bound avidin is eliminated by the observation that avidin linked to E through other means does not render the cells complement activating [4, 5, 24] . Cross-linking of other biotinylated proteins is thus likely to be responsible for the activation event which, combined with neutralization of the complement regulatory molecules CD59 and DAF, renders AvBE exquisitely susceptible to destruction by complement.
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